Specific programme: ARSEP Foundation on Multiple Sclerosis Research 2016
UPV/EHU Partner Status: Research project grantee
UPV/EHU PI: Susana Mato
Project start: 01/11/2015
Project end:   30/11/2017
 

Brief description:  Our working hypothesis, based on previously obtained results (Bernal-Chico et al., 2015), is that is that attenuation of 2-AG hydrolysis may be a useful strategy for the treatment of myelin diseases. The general objective of this project is to rationally evaluate the potential of targeting the serine hydrolases MAGL and ABHD6 to treat MS. With this aim we will compare the ability of drugs that inhibit each enzyme to attenuate different pathological features of the disease as well as to promote repair mechanisms both in vitro and in vivo. In addition we will explore the appearance of molecular adaptations associated to the chronic use of MAGL or ABHD6 inhibitors and that may limit the efficacy of the long-term efficacy of these compounds.